Patents Assigned to Protiva Biotherapeutics Inc.
-
Publication number: 20110091525Abstract: The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such compositions, liposomes, SNALP, and SPLP.Type: ApplicationFiled: August 6, 2010Publication date: April 21, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Ian MacLachlan, Ellen Grace Ambegia
-
Publication number: 20110076335Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: ApplicationFiled: June 30, 2010Publication date: March 31, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Patent number: 7915399Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains full RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: GrantFiled: June 8, 2007Date of Patent: March 29, 2011Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge
-
Publication number: 20110071208Abstract: The present invention provides novel, stable nucleic acid-lipid particles comprising one or more Dicer-substrate dsRNAs and/or small hairpin RNAs (shRNAs), methods of making the particles, and methods of delivering and/or administering the particles (e.g., for the treatment of a disease or disorder). In some embodiments, the nucleic acid-lipid particles of the invention comprise Dicer-substrate dsRNAs and/or shRNAs. In other embodiments, the nucleic acid-lipid particles of the invention comprise Dicer-substrate dsRNAs and/or shRNAs in combination with one or more additional interfering RNAs (e.g., siRNA, aiRNA, and/or miRNA). In further embodiments, the Dicer-substrate dsRNAs and/or shRNAs present in the nucleic acid-lipid particles of the invention are chemically synthesized.Type: ApplicationFiled: June 4, 2010Publication date: March 24, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Marjorie Robbins, Adam Judge
-
Publication number: 20110060032Abstract: The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.Type: ApplicationFiled: August 6, 2010Publication date: March 10, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lome R. Palmer, James Heyes
-
Patent number: 7901708Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: GrantFiled: June 30, 2003Date of Patent: March 8, 2011Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd Brian Jeffs, Lorne R. Palmer, Cory Giesbrecht, Noelle Giesbrecht, legal representative
-
Patent number: 7807815Abstract: The present invention provides siRNA molecules and methods of using such siRNA molecules to modulate an immune response and to silence expression of a target gene.Type: GrantFiled: June 30, 2005Date of Patent: October 5, 2010Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge, James Heyes, Lorne Palmer
-
Patent number: 7803397Abstract: The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such compositions, liposomes, SNALP, and SPLP.Type: GrantFiled: September 15, 2004Date of Patent: September 28, 2010Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Ian MacLachlan, Ellen Grace Ambegia
-
Patent number: 7799565Abstract: The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.Type: GrantFiled: June 7, 2005Date of Patent: September 21, 2010Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lorne R. Palmer, James Heyes
-
Patent number: 7745651Abstract: The present invention provides compositions comprising cationic lipids, liposomes and nucleic acid-lipid particles comprising the cationic lipids, and methods of using such compositions, liposomes, and nucleic acid-lipid particles.Type: GrantFiled: June 7, 2005Date of Patent: June 29, 2010Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Ian MacLachlan, Lorne R. Palmer
-
Publication number: 20100130588Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: April 15, 2009Publication date: May 27, 2010Applicant: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20090291131Abstract: The present invention provides compositions comprising interfering RNA (e.g., siRNA, aiRNA, miRNA) that target polo-like kinase 1 (PLK-1) expression and methods of using such compositions to silence PLK-1 expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence PLK-1 expression and methods of use thereof. The present invention also provides serum-stable nucleic acid-lipid particles (e.g., SNALP) comprising an interfering RNA molecule described herein, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing PLK-1 gene expression by administering an interfering RNA molecule described herein to a mammalian subject. The present invention additionally provides methods of identifying and/or modifying PLK-1 interfering RNA having immunostimulatory properties.Type: ApplicationFiled: December 23, 2008Publication date: November 26, 2009Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge
-
Publication number: 20090270481Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: ApplicationFiled: January 23, 2009Publication date: October 29, 2009Applicant: Protiva Biotherapeutics,Inc.Inventors: Ian MacLachlan, Adam Judge, Amy C.H. Lee, Vandana Sood
-
Publication number: 20090149403Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.Type: ApplicationFiled: May 29, 2007Publication date: June 11, 2009Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge, Vandana Sood, James Heyes, Lloyd B. Jeffs, Lorne Palmer
-
Publication number: 20080249046Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains full RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: ApplicationFiled: June 8, 2007Publication date: October 9, 2008Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge
-
Publication number: 20080171716Abstract: The present invention provides methods of modulating the activation of certain Toll-like receptors (TLRs) such as TLR7/8 using chemically modified nucleic acid molecules. The present invention also provides methods of using such modified nucleic acid molecules to treat diseases or disorders associated with TLR7/8 activation such as systemic lupus erythematosus. The present invention further provides compositions comprising a combination of modified nucleic acid molecules and nucleic acid molecules that silence expression of one or more target sequences. Methods of using such compositions to reduce or abolish target gene expression without inducing cytokine production are also provided.Type: ApplicationFiled: August 15, 2007Publication date: July 17, 2008Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Marjorie Robbins, Adam Judge
-
Publication number: 20070218122Abstract: The present invention provides siRNA molecules that target influenza virus gene expression and methods of using such siRNA molecules to silence influenza virus gene expression. The present invention also provides nucleic acid-lipid particles that target influenza virus gene expression comprising an siRNA that silences influenza virus gene expression, a cationic lipid, and a non-cationic lipid.Type: ApplicationFiled: November 17, 2006Publication date: September 20, 2007Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Marjorie Robbins
-
Publication number: 20070135370Abstract: The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.Type: ApplicationFiled: October 20, 2006Publication date: June 14, 2007Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Vandana Sood, Thomas Geisbert, Lisa Hensley, Elliott Kagan
-
Publication number: 20070135372Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: ApplicationFiled: November 2, 2006Publication date: June 14, 2007Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge
-
Publication number: 20070054873Abstract: The present invention provides methods for minimizing or inhibiting immune responses to immunostimulatory nucleic acids by pretreating with one or more doses of a glucocorticoid prior to nucleic acid administration. The nucleic acids are typically administered using a lipid-based carrier system such as a nucleic acid-lipid particle or liposome. As a result, patients following a glucocorticoid dosing regimen advantageously benefit from nucleic acid therapy without suffering any of the immunostimulatory side-effects associated with such therapy.Type: ApplicationFiled: August 28, 2006Publication date: March 8, 2007Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge